share_log

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT:其他
美股sec公告 ·  05/03 18:06
牛牛AI助理已提取核心訊息
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by Accession Number 0001214659-24-007916 and File Number 333-270353, was categorized under the submission type POS AM. This notice of effectiveness by the SEC is a significant regulatory milestone for Biodexa Pharmaceuticals.
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by Accession Number 0001214659-24-007916 and File Number 333-270353, was categorized under the submission type POS AM. This notice of effectiveness by the SEC is a significant regulatory milestone for Biodexa Pharmaceuticals.
美國證券交易委員會(SEC)宣佈,Biodexa Pharmicals Plc的申請已於2024年5月2日生效。該提交的材料由註冊號 0001214659-24-007916 和文件編號爲 333-270353 進行識別,歸類爲 POS AM 提交類型。美國證券交易委員會的這份生效通知是Biodexa製藥公司重要的監管里程碑。
美國證券交易委員會(SEC)宣佈,Biodexa Pharmicals Plc的申請已於2024年5月2日生效。該提交的材料由註冊號 0001214659-24-007916 和文件編號爲 333-270353 進行識別,歸類爲 POS AM 提交類型。美國證券交易委員會的這份生效通知是Biodexa製藥公司重要的監管里程碑。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。